FULC Stock Analysis: Buy, Sell, or Hold?
FULC - Fulcrum Therapeutics, Inc. Common Stock
$7.44
-0.28 (-3.63%)
▼
5d:
-1.2%
30d:
+10.55%
90d:
-31.99%
BUY
HIGH Confidence
Analysis Updated: Apr 28, 2026 12:00 AM ET
Earnings: May 18, 2026
18d
Smart Money Accumulation
FULC is down 5.4% this week, but smart money is accumulating calls. Top strike: $10 2026-06-18 with 418 OI. Call ratio: 100% View Scanner →
Strength: 7.7/10
Get Alerted When FULC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: FULC shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: FULC shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: FULC is currently trading at $7.44, which is considered fair relative to its 30-day fair value range of $7.11 to $8.08.
Technical Outlook: Technically, FULC is in a strong downtrend. Immediate support is located at $7.01, while resistance sits at $8.37. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $19.00 (+155.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, FULC is in a strong downtrend. Immediate support is located at $7.01, while resistance sits at $8.37. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $19.00 (+155.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$7.11 -
$8.08
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
75.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.6%)
- BULLISH: Trading 155.4% below Wall St target ($19.00)
Trading Range Analysis
30-Day Trading Range
$7.11 -
$8.08
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$1.33
(17.8%)
Support & Resistance Levels
Support Level
$7.01
Resistance Level
$8.37
Current Trend
Strong Downtrend
Technical data as of
Apr 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.91
Wall Street Target
$19.00
(+155.4%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: April 29, 2026 4:25 AM ET
Data refreshes hourly during market hours. Next update: 5:25 AM
Data refreshes hourly during market hours. Next update: 5:25 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FULC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Robert J Gould
SELL
15000 shares
2026-01-02
Ra Capital Management, L…
SELL
4175139 shares
2025-12-08
Robert J Gould
SELL
15000 shares
2025-11-19
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1035 | 52 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 53 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$298 | 58 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 67 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 47 HOLD |
Advanced FULC Option Strategies
Professional options setups generated by AI based on today's FULC price and gamma walls.
